Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + 5-FU/LV in Metastatic Colorectal Cancer (AVF2192g)
NCT00109226Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2000
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing Bevacizumab + 5-FU/LV with Placebo + 5-FU/LV (2 arms). Primary endpoint: Overall Survival. Started Aug 2000; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00109226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109226.